Prevalence of chronic pain with neuropathic characteristics in the general population

Bouhassira, Didier; Lantéri-Minet, Michel; Attal, Nadine; Laurent, Bernard; Touboul, Chantal

doi:10.1016/j.pain.2007.08.013

Cited by 1,453 publications

(1,096 citation statements)

References 47 publications

Supporting

Mentioning

953

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, aging may be associated with desensitization of the central nervous system and, therefore, a lower likelihood of developing CS and NP. Neither theory has been consistently supported in the literature, where advanced age has variably been associated with NP symptoms (12,13). Further study is warranted to understand the role of age in the development of NP among people with chronic pain conditions.…”

Section: Discussionmentioning

confidence: 99%

The nerve of osteoarthritis pain

Hochman¹,

French²,

Bermingham³

et al. 2010

Arthritis Care & Research

168

142

View full text Add to dashboard Cite

Objective. Cumulative data suggest that central sensitization may contribute to pain in osteoarthritis (OA) and present with symptoms typically associated with neuropathic pain (NP). We evaluated the responses from focus group participants on the knee OA pain experience for pain descriptions that suggest NP. Methods. Focus group transcripts were analyzed by 2 independent assessors for unprompted use of pain descriptors that suggested NP. Items from validated NP symptom-based questionnaires were used to guide the analysis. Data on sociodemographic factors, duration of knee OA, and OA disease and pain severity (using the Western Ontario and McMaster Universities Osteoarthritis Index and a numerical rating scale) were obtained from questionnaires administered after focus group completion. These factors were compared among participants who did and did not use descriptors that suggested NP. Results. Transcripts from 80 knee OA participants were analyzed. A range of NP descriptors was used to characterize their knee symptoms, including burning, tingling, numbness, and pins and needles. The proportion of participants who used NP descriptors was 0.34 (95% confidence interval 0.24 -0.45). Those who used NP descriptors were younger (P ‫؍‬ 0.003) and, although not statistically different, more likely to be women, with higher pain intensity and OA severity and longer OA duration, than those who did not use NP descriptors. Conclusion. During focus groups, a subset of adults with chronic, symptomatic knee OA used pain quality descriptors that were suggestive of NP. Elicitation of NP descriptors in people with OA may help identify those who could benefit from further evaluation and perhaps treatment for NP.

show abstract

Section: Discussionmentioning

confidence: 99%

The nerve of osteoarthritis pain

Hochman¹,

French²,

Bermingham³

et al. 2010

Arthritis Care & Research

168

142

View full text Add to dashboard Cite

show abstract

“…There are, however, wide regional variations ranging from a high of 18.1% in Oceania down to 2.3% in Africa for CC [58]. Chronic neuropathic pain has been found to be more frequent in women [61], and this is consistent with refractory CC [62,63]. The basic neurobiological mechanisms and pathologies of refractory CC and chronic pain show substantial homologies.…”

Section: Introductionmentioning

confidence: 99%

An update and systematic review on drug therapies for the treatment of refractory chronic cough

Ryan

Vertigan

Birring

2018

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction: Chronic Cough (CC) is common and often associated with significant comorbidity and decreased quality of life. In up to 50% of cases, the cough is refractory despite extensive investigation and treatment trials. It is likely that the key abnormality in refractory CC is dysfunctional, hypersensitive sensory nerves, similar to conditions such as laryngeal hypersensitivity and neuropathic pain.Areas covered: The aim of this systematic review is to assess drug therapies for refractory CC. The authors review the current management of CC and provide discussion of the similarities between neuropathic pain and refractory CC. They review repurposed and new pharmacological treatments. Several meta-analyses were performed to compare the efficacy of treatments where possible.Expert opinion: Repurposed pain medications such as gabapentin and pregabalin reduce the frequency of cough and improve quality of life. Along with speech pathology, they are important and alternate treatments for refractory CC. However, more treatments are needed and the P2X3 ion channel receptor antagonists show the most promise. With a better understanding of neuronal activation and sensitisation and their signal processing in the brain, improved animal models of cough, and the use of validated cough measurement tools, more effective treatments will develop.

show abstract

“…Painful neuropathy or peripheral neuropathic pain (PNP) is a common neurological condition according to the revised International Association for the Study of Pain (IASP) definition (Treede et al., 2008), and is estimated to affect ~7–8% of the general population in Europe (Torrance et al., 2006; Bouhassira et al., 2008). Managing patients with PNP is challenging (Dworkin et al., 2007, 2010; Finnerup et al., 2010; Finnerup, Attal et al ., 2015); it often becomes chronic, with marked long‐term reductions in health‐related quality of life (HRQOL) (O'Connor, 2009), decreased individual productivity and increased patient and healthcare expenditure (Rodríguez et al., 2007; Navarro et al., 2011).…”

Section: Introductionmentioning

confidence: 99%

Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain

Haanpää

Cruccu

Nurmikko

et al. 2015

European Journal of Pain

View full text Add to dashboard Cite

BackgroundClinical trials have not yet compared the efficacy of capsaicin 8% patch with current standard therapy in peripheral neuropathic pain (PNP).ObjectivesHead‐to‐head efficacy and safety trial comparing the capsaicin patch with pregabalin in PNP.MethodsOpen‐label, randomized, multicentre, non‐inferiority trial. Patients with PNP, aged 18–80 years, were randomly assigned to either the capsaicin 8% patch (n = 282) or an optimised dose of oral pregabalin (n = 277), and assessed for a ≥30% mean decrease in Numeric Pain Rating Scale (NPRS) score from baseline to Week 8. Secondary endpoints included optimal therapeutic effect (OTE), time‐to‐onset of pain relief and treatment satisfaction.ResultsThe capsaicin 8% patch was non‐inferior to pregabalin in achievement of a ≥30% mean decrease in NPRS score from baseline to Week 8 (55.7% vs. 54.5%, respectively; Odds ratio: 1.03 [95% CI: 0.72, 1.50]). The proportion of patients achieving OTE at Week 8 was 52.1% for the capsaicin 8% patch versus 44.8% for pregabalin (difference: 7.3%; 95% CI: −0.9%, 15.6%). The median time‐to‐onset of pain relief was significantly shorter for capsaicin 8% patch versus pregabalin (7.5 vs. 36.0 days; Hazard ratio: 1.68 [95% CI: 1.35, 2.08]; p < 0.0001). Treatment satisfaction was also significantly greater with the capsaicin 8% patch versus pregabalin. TEAEs were mild‐to‐moderate in severity, and resulted in treatment discontinuation only with pregabalin (n = 24). Systemic adverse drug reactions ranged from 0 to 1.1% with capsaicin 8% patch and 2.5 to 18.4% with pregabalin.ConclusionsThe capsaicin 8% patch provided non‐inferior pain relief to an optimized dose of pregabalin in PNP, with a faster onset of action, fewer systemic side effects and greater treatment satisfaction.

show abstract

Prevalence of chronic pain with neuropathic characteristics in the general population

Cited by 1,453 publications

References 47 publications

The nerve of osteoarthritis pain

The nerve of osteoarthritis pain

An update and systematic review on drug therapies for the treatment of refractory chronic cough

Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain

Contact Info

Product

Resources

About